Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.

ABSTRACT:

Background

Non-alcoholic steatohepatitis (NASH) is characterised by hepatic lipid accumulation, cell injury, inflammation and fibrosis. Insulin resistance, a hallmark of type 2 diabetes (T2D) and obesity, is a key pathogenic driver of NASH. Other than difficult-to-maintain lifestyle changes, there are no approved treatments for NASH. Due to their effects on multiple pathophysiological processes, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been tested in disorders related to insulin resistance and metabolic defects.

Aims

To summarise studies of GLP-1RAs relevant to the treatment of NASH.

Methods

PubMed searches were performed and results were compiled.

Results

Large trials with GLP-1RAs in T2D demonstrate highly effective glucose lowering, with bod

SUBMITTER: Barritt AS 

PROVIDER: S-EPMC9310586 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature